A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
A plug-and-play export pathway helps regional brands reach Asia without building overseas operations
Updated
March 17, 2026 1:01 AM
Coupang headquarters in Silicon Valley. PHOTO: ADOBE STOCK
Two western Pennsylvania companies — Kate’s Real Food and Healthy Origins — are expanding beyond the U.S. through a partnership with Coupang.
Coupang, a U.S.-technology and Fortune 150 company, operates one of the largest e-commerce platforms in South Korea. It allows American sellers to reach customers overseas without setting up their own distribution networks. Businesses ship products to a domestic Coupang logistics facility. From there, the company manages storage, fulfillment and delivery directly to customers abroad.
For Kate’s Real Food and Healthy Origins, this system opens the door to new markets without requiring on-the-ground operations. Kate’s Real Food makes organic energy and protein bars. Healthy Origins is a family-owned supplements business based near Pittsburgh. Both are now selling to customers in South Korea and in Healthy Origins’ case, Taiwan as well.
That structure addresses a practical gap for growing brands: how to access international demand without building international operations. Instead of navigating foreign warehousing and retail partnerships independently, sellers plug into an existing marketplace and logistics system.
“At Coupang, we’re proud to help thousands of American small and medium-sized businesses, agricultural producers and larger brands sell their goods to customers around the world”, said Coupang vice president Bill Anaya. “We’ve built an innovative, AI-driven export engine that enables great American entrepreneurs — like those who created Kate’s Real Food and Healthy Origins — to expand their horizons, find new revenue abroad and keep growing their local teams".
For Kate’s Real Food, the move marks its entry into South Korea for the first time. For Healthy Origins, the results have been measurable. The company reports that sales of its products on the platform have increased more than 50% year over year since partnering with Coupang. It has also expanded into Taiwan.
“Partnering with Coupang has been a significant step forward for our business”, said Bret Eby, CEO of Healthy Origins. “Coupang makes it easier to deliver a great shopping experience and we’ve appreciated the collaboration and support throughout the process. Its scale, efficiency and consumer reach in Korea are unmatched and launching on Coupang allowed us to elevate our presence and connect with customers in a much more impactful and direct way”.
The broader relevance lies in the model itself. Digital marketplaces are building integrated cross-border infrastructure. That shift changes what international expansion requires. Smaller regional brands no longer need to replicate warehousing, logistics and retail partnerships in every new market. Instead, they can plug into an existing system and reach customers abroad.
In this case, two Pennsylvania companies are doing exactly that. Their expansion illustrates how platform-led trade is reshaping the path from local operations to global reach.